CDRH touts lack of application backlog

Article

The Food and Drug Administration’s Center for Devices and Radiological Health (CDRH) announced this month that for the second year in a row, its premarket review program had no backlog of 510(k)s, premarket approval applications, or PMA supplements

The Food and Drug Administration’s Center for Devices and Radiological Health (CDRH) announced this month that for the second year in a row, its premarket review program had no backlog of 510(k)s, premarket approval applications, or PMA supplements for fiscal year 1998.

Average total review time for 510(k) applications was 114 days an improvement over 130 in 1997 and 145 in 1996. Median review time for 510(k)s that cleared in fiscal year 1998 was 83 days. CDRH cleared 46 PMAs in 1998, according to the agency. The average review time of PMAs from submission to approval was roughly 12 months, 25% less than fiscal year 1997 and 50% less than fiscal year 1996. The median total time the CDRH took to clear PMAs in 1998 was about nine months.

The program attributed improved clearance times to more companies consulting with the FDA as they plan clinical studies. They also credited pilot management initiatives the CDRH implemented this year.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.